OncoMed Pharmaceuticals Presents Phase 1 Data in Solid Tumor Patients for the First-in-Class Wnt Pathway Targeting Antibody Vantictumab at ASCO )--OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, today highlighted new data for ... (more)
http://eon.businesswire.com/news/eon/20130603005566/en/OncoMed-Pharmaceuticals-Presents-Phase-1-Data-Solid
http://eon.businesswire.com/news/eon/20130603005566/en/OncoMed-Pharmaceuticals-Presents-Phase-1-Data-Solid
No comments:
Post a Comment